SOURCE: Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

April 27, 2016 08:00 ET

Critical Outcome Technologies Augments Advisory Board Drug Development Experience

LONDON, ON--(Marketwired - April 27, 2016) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announced today the addition of Dr. Nancy Chang to its Scientific Advisory Board to support the Company in the clinical development of its lead cancer drug candidate, COTI-2, and its other pipeline compounds. 

"We are delighted to have attracted such an accomplished research scientist, businesswoman and philanthropist as Dr. Chang to add to the quality and depth of our Scientific Advisory Board," said Dr. Wayne Danter, Chief Executive Officer. "We believe the combination of Dr. Chang's scientific experience in developing first-in-class therapeutic products for significant unmet medical needs in treating major human diseases and her business acumen will bring a unique perspective and additional resources to our Company, to our COTI-2 clinical development program and to our licensing and partnership opportunities."

About Dr. Nancy Chang

Dr. Chang was born and educated in Taiwan and received her Ph.D. in biological chemistry from Harvard University. Her early research activities were at the Roche Institute of Molecular Biology developing recombinant alpha and beta interferons. Dr. Chang subsequently joined Centocor (now a Division of Johnson and Johnson) where she held several leadership positions from 1981 to 1986 in the development of antibody based diagnostic and therapeutic products and also conducted pioneering research and development work in the HIV field. In 1986, Dr. Chang moved to Houston, TX. with her family and joined Baylor College of Medicine as an Associate Professor of Virology until 1991.

In 1986, Dr. Chang co-founded a biotechnology company, Tanox, Inc. that subsequently developed a breakthrough asthma drug, Xolair, approved by the U.S. FDA in June 2003 for treating patients with moderate to severe asthma. Dr. Chang served as the President & CEO of Tanox until it was acquired by Genentech in 2007 for USD $919 million.

Dr. Chang's published research includes over 35 papers on topics including monoclonal antibodies and HIV. She has been awarded seven patents.

In addition to her research work, Dr. Chang has served on the board of directors of several enterprises including: the Federal Reserve Bank in Houston, Project Hope, BioHouston, Charles River Laboratories, and the Board of Visitors of the University of Texas M.D. Anderson Cancer Center. Dr. Chang is also an angel investor in health-care entrepreneurships and performs philanthropic work in community health and education projects. Dr. Chang was also the chairman and senior managing director of OrbiMed's Caduceus Asia partner fund, a fund of Orbimed Advisors, the largest investment firm focused on the healthcare sector, from 2009-2013. Currently Dr. Chang is an adjunct professor at the Departments of Medicine and Genetics at Baylor College of Medicine.

For additional information on Dr. Chang please visit her Wikipedia page at:

About Critical Outcome Technologies Inc.

COTI is a clinical stage biopharmaceutical company advancing the treatment of cancer through targeted therapeutics. The Company's lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. The initial therapeutic indication is in gynecologic cancers, which includes ovarian, cervical, and endometrial cancers; a Phase 1 clinical trial began at MD Anderson Cancer Center in December 2015. The Company has secured orphan drug status for the ovarian indication in the U.S. and is planning additional studies in other cancer indications such as head and neck, Li-Fraumeni Syndrome, and acute myelogenous leukemia, based upon more than ten animal xenograft models showing both single and combination agent activity of COTI-2 with other leading cancer drugs. Preclinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.

Follow @CriticalOutcome on Twitter at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice to Readers

Information contained in this press release may contain certain statements, which constitute "forward-looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statements "… will bring a unique perspective and additional resources to our Company, to our COTI-2 clinical development program and to our licensing and partnership opportunities" is forward-looking statement. Forward‐looking statements, by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward‐looking statements. Management of COTI considers the assumptions on which these forward‐looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

Contact Information